FDA Approves Drug for Breast Cancer Resistant to First-Line TreatmentsOctober 17th 2007
ROCKVILLE, Md. -- Bristol-Myers Squibb said its metastatic breast cancer drug ixabepilone (Ixempra) has received FDA approval for treatment of women with metastatic or locally advanced treatment-resistant breast cancer.
Colorectal Cancer Leads Decline in Cancer Death RatesOctober 15th 2007
Cancer death rates fell by about 2.1% per year from 2002 to 2004, compared with a 1.1% per year decline from 1993 though 2002, according to annual report to the nation from the Centers for Disease Control and Prevention, the American Cancer Society, the National Cancer Institute, and the North american Association of Central Cancer Registries.
FDA Approves First-in-Class Integrase Inhibitor for Treatment-Resistant HIV-1October 15th 2007
WHITEHOUSE STATION, N.J. -- The FDA has approved raltegravir (Isentress) as part of a combination regiment for treatment for multi-resistant HIV-1 infection in adults, according to an announcement from Merck.
Cutbacks in Medicare Chemotherapy Payments Have Little Impact on CareOctober 8th 2007
DURHAM, N.C. -- Cancer patients are not waiting longer for chemotherapy, nor are they traveling greater distances to receive treatment, despite predictions of access issues when Medicare reduced payment for infusion therapy.
NEJM Raises Questions About Detachment When a Patient DiesSeptember 26th 2007
BOSTON -- When a patient dies during a "code call" in the hospital, the residents, nurses, and technicians who responded to the emergency might stop for just a moment and pay respects to the life that was lost, suggested a Harvard internist.
ACS Breast Cancer Report Cites Gains in Breast Cancer SurvivalSeptember 26th 2007
ATLANTA -- The breast cancer mortality rate in the U.S. has been edging down by 2% a year since 1990 and the incidence of new cases has declined by 3.5% per year from 2001 to 2004, according to the American Cancer Society/
FDA Warns of Sudden Death Risk with IV Haloperidol (Haldol)September 18th 2007
ROCKVILLE, Md. -- The FDA has issued a safety alert warning physicians that haloperidol (Haldol) given intravenously or at higher than recommended doses may increase the risk of cardiovascular events including sudden death, QT prolongation, and Torsades de Pointes.
FDA Wants Cancer Warning and UVA Protection Rating on Sunscreen LabelsAugust 23rd 2007
ROCKVILLE, Md. -- The FDA called today for sunscreen labels to include a warning about skin cancer and add information about ultraviolet A (UVA) protection as well as the ultraviolet B (UVB) ratings that are now standard.